Research & development Korean listed companies

Grouped by the industry code each company registered with DART. Sorted by latest quarterly operating profit.

Companies78

Operating profit−₩132bnlatest quarter, combined

Operating losses24

Average dividend yield3.2%2 payers

There are 78 KOSPI and KOSDAQ companies classified under research & development. Combined operating profit for the latest reported quarter across 27 of them was −₩132bn; 24 posted an operating loss and 1 swung to a profit from a loss a year earlier. The largest by quarterly operating profit were HLB Pharmaceutical, DreamCIS and Dt&cro. The median operating margin across the 13 with reported revenue was -29.4%. 2 paid a cash dividend, with an average reported yield of 3.2%.

Research & development companies

Company	Latest quarter op. profit	Dividend yield	Articles 30d	Signals
HLB Pharmaceutical KOSDAQ	₩847m	–	44	Share pledge Asset deal
DreamCIS KOSDAQ	₩469m -83% YoY	–	4	–
Dt&cro KOSDAQ	₩433m	–	4	Turnaround Litigation Supply contract
Kainos Medicine KOSDAQ	−₩582m	–	1	4 quarters of losses
Eone Diagnomics Genome Center KOSDAQ	−₩705m	–	1	Delisting / halt risk 4 quarters of losses
3billion KOSDAQ	−₩1.2bn	–	35	4 quarters of losses
Cytogen KOSDAQ	−₩1.4bn	–	0	Supply contract 4 quarters of losses
Naturalendo Tech KOSDAQ	−₩1.6bn	–	4	4 quarters of losses
Pharos iBio KOSDAQ	−₩2.0bn	–	14	Clinical trial filing 4 quarters of losses
HLB bioStep KOSDAQ	−₩2.3bn	–	3	Swung to loss 4 quarters of losses
ViGenCell KOSDAQ	−₩2.6bn	–	10	4 quarters of losses
Inventera KOSDAQ	−₩2.7bn	–	21	Insider buying Clinical trial filing 4 quarters of losses
Helixmith KOSDAQ	−₩2.7bn	–	3	4 quarters of losses
Genomictree KOSDAQ	−₩2.7bn	–	11	4 quarters of losses
Oncocross KOSDAQ	−₩2.9bn	–	4	Insider buying 4 quarters of losses
TiumBio KOSDAQ	−₩3.2bn	–	9	Major holder adding Share pledge M&A / stake deal 4 quarters of losses
AprilBio KOSDAQ	−₩3.4bn	–	33	Control change 4 quarters of losses
IMBiologics KOSDAQ	−₩3.4bn	–	10	–
LabGenomics KOSDAQ	−₩3.5bn	–	10	Buyback Delisting / halt risk 4 quarters of losses
Kanaph Therapeutics KOSDAQ	−₩3.6bn	–	14	Insider buying 4 quarters of losses
MedPacto KOSDAQ	−₩3.6bn	–	39	Clinical trial filing 4 quarters of losses
Vaxcell-Bio Therapeutics KOSDAQ	−₩3.7bn	–	33	4 quarters of losses
Qurient KOSDAQ	−₩7.0bn	–	41	Insider buying 4 quarters of losses
Genexine KOSDAQ	−₩7.1bn	–	12	Dilution risk Private placement 4 quarters of losses
Curocell KOSDAQ	−₩7.7bn	–	51	Insider buying New 5% holder Major holder adding Clinical trial filing 4 quarters of losses
D&D Pharmatech KOSDAQ	−₩13.6bn	–	72	M&A / stake deal 4 quarters of losses
LigaChem Biosciences KOSDAQ	−₩50.4bn	–	69	4 quarters of losses
SK biopharmaceuticals KOSPI	–	–	324	–
Alteogen KOSDAQ	–	0.1%	256	Dilution risk Private placement M&A / stake deal
SillaJen KOSDAQ	–	–	44	Clinical trial filing 4 quarters of losses
Onconic Therapeutics KOSDAQ	–	–	43	–
OliX Pharmaceuticals KOSDAQ	–	–	42	Clinical trial filing 4 quarters of losses
GI Innovation KOSDAQ	–	–	41	Share pledge Insider buying Clinical trial filing 4 quarters of losses
Voronoi KOSDAQ	–	–	38	Dilution risk Clinical trial filing 4 quarters of losses
Rznomics KOSDAQ	–	–	37	Insider buying 4 quarters of losses
Inventage Lab KOSDAQ	–	–	27	Clinical trial filing 4 quarters of losses
Aribiolab KOSDAQ	–	–	24	Share pledge Dilution risk Private placement Control change 4 quarters of losses
Y-Biologics KOSDAQ	–	–	24	Insider buying 4 quarters of losses
Proteina KOSDAQ	–	–	20	Dilution risk Private placement 4 quarters of losses
Organoidsciences KOSDAQ	–	–	19	4 quarters of losses
EyeGene KOSDAQ	–	–	17	Insider buying Major holder adding Clinical trial filing 4 quarters of losses
CJ Bioscience KOSDAQ	–	–	13	M&A / stake deal 4 quarters of losses
NeoImmuneTech KOSDAQ	–	–	13	4 quarters of losses
Aimed Bio KOSDAQ	–	–	12	Clinical trial filing
Penetrium Bioscience KOSDAQ	–	–	11	Share pledge Insider buying 4 quarters of losses
ToolGen KOSDAQ	–	–	11	4 quarters of losses
Kolmar BioTech KOSDAQ	–	–	11	Insider buying
Aptabio Therapeutics KOSDAQ	–	–	11	Clinical trial filing 4 quarters of losses
MOA Life Plus KOSDAQ	–	–	10	Share pledge Insider selling Major holder adding Dilution risk Private placement Control change Delisting / halt risk 4 quarters of losses
JS Link KOSDAQ	–	–	9	Asset deal 4 quarters of losses
Cellid KOSDAQ	–	–	9	Dilution risk Private placement Litigation Control change 4 quarters of losses
Prestige BioPharma KOSPI	–	–	9	4 quarters of losses
Genematrix KOSDAQ	–	–	8	Clinical trial filing
ImmuneOncia Therapeutics KOSDAQ	–	–	7	Clinical trial filing 4 quarters of losses
INGENIA Therapeutics KOSDAQ	–	–	7	Clinical trial filing
KoBioLabs KOSDAQ	–	–	6	4 quarters of losses
Geninus KOSDAQ	–	–	6	Insider buying 4 quarters of losses
Mezzion Pharma KOSDAQ	–	–	4	Insider buying 4 quarters of losses
CG Invites KOSDAQ	–	–	3	Share pledge M&A / stake deal 4 quarters of losses
Biotoxtech KOSDAQ	–	–	3	Major holder adding Insider buying 4 quarters of losses
Epi Biotech KONEX	–	–	3	–
BioInfra KOSDAQ	–	6.2%	2	Major holder adding M&A / stake deal Delisting / halt risk Dividend cut High dividend
Choolip & Sciences KOSDAQ	–	–	2	4 quarters of losses
Abion KOSDAQ	–	–	1	Clinical trial filing Supply contract 4 quarters of losses
NovMetaPharma KONEX	–	–	1	Dilution risk Private placement
Medizen Humancare KONEX	–	–	1	–
ProGen KONEX	–	–	1	Share pledge
curacle KOSDAQ	–	–	1	–
Ensol Biosciences KONEX	–	–	0	–
Cronex KONEX	–	–	0	–
Invites Biocore KONEX	–	–	0	–
AngioLab KONEX	–	–	0	–
IntoCell KOSDAQ	–	–	0	4 quarters of losses
Moogene Medi KONEX	–	–	0	–
Future Medicine KONEX	–	–	0	Delisting / halt risk
Quratis KOSDAQ	–	–	0	4 quarters of losses
HEM Pharma KOSDAQ	–	–	0	4 quarters of losses
IMBdx KOSDAQ	–	–	0	4 quarters of losses

Industry codes are the primary business each company registered with DART and may not reflect its full business mix. Figures come from DART filings; prices are not included. Not investment advice.